Determination of donepezil in human plasma by HPLC-MS

Yaoxue Xuebao

Volumn 38, Issue 3, 2003, Pages 203-206

  Lu, Yi Hong ^a   Wen, Hong Mei ^b   Li, Wei ^b   Chi, Yu Mei ^b   Zhang, Zheng Xing ^c  

^a Jiangsu Institute for Drug Control   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Donepezil; HPLC MS; Loratadine; Plasma concentration

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ARTICLE; BLOOD; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METHODOLOGY;

CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDANS; MASS SPECTROMETRY; PIPERIDINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 2142687619     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Mihara M, Ohnishi A, Tomono Y, et al Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers [J]. Int J Clin Pharmacol Ther Toxicol, 1993,31(5):223-229.
2. Rho JP, Lipson LG. Focus on donepezil: a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease [J]. Formulary, 1997,32(7):677-678.
3. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study [J]. Arch Intern Med, 1998,158(9):1021- 1031.
4. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodymic profile of donepezil HCl following single oral doses [J]. Br J Clin Pharmacol, 1998,46(Suppl 1):1-6.
5. Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacodynamic profile of donepezil HCl following multiple oral doses [J]. Br J Clin Pharmacol, 1998,46(Suppl 1):7-12.
6. Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects [J]. J Clin Pharmacol, 1993,33(11): 1086-1091.